APYX:NSD-Apyx Medical Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 8.25

Change

-2.03 (-19.75)%

Market Cap

USD 0.37B

Volume

0.61M

Avg Analyst Target

USD 12.20 (+47.88%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


APYX Stock Forecast & Price:
Based on the Apyx Medical Inc stock forecasts from 2 analysts, the average analyst target price for Apyx Medical Inc is USD 12.20 over the next 12 months. Apyx Medical Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Apyx Medical Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Apyx Medical Inc’s stock price was USD 8.25. Apyx Medical Inc’s stock price has changed by -21.05% over the past week, +22.77% over the past month and -25.88% over the last year.

About Apyx Medical Inc (APYX:NSD)

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Gene ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-12 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

+1.59 (+1.80%)

USD34.96B 205.21 88.80
PODD Insulet Corporation

+6.62 (+2.51%)

USD18.33B 498.26 127.76
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD ABIOMED Inc

+2.66 (+0.91%)

USD13.28B 58.91 43.54
SWAV Shockwave Medical Inc

+7.61 (+2.70%)

USD10.03B 341.73 123.23
BRKR Bruker Corporation

-0.19 (-0.31%)

USD9.18B 34.44 19.15
IART Integra LifeSciences Holdings

+0.89 (+1.58%)

USD4.72B 28.97 16.36
IRTC iRhythm Technologies Inc

-0.38 (-0.25%)

USD4.56B N/A -39.96
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67
TNDM Tandem Diabetes Care Inc

+0.33 (+0.62%)

USD3.64B 707.88 556.41

ETFs Containing APYX

Symbol Name Weight Mer Price(Change) Market Cap
PQSG PGIM ETF Trust - PGIM QMA.. 0.00 % 0.29 %

N/A

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -35.65% 42% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.65% 42% F 31% F
Trailing 12 Months  
Capital Gain -24.38% 69% D+ 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.38% 69% D+ 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 21.50% 57% F 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.50% 57% F 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 63.26% 46% F 21% F
Risk Adjusted Return 33.99% 66% D 67% D+
Market Capitalization 0.37B 64% D 52% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 4.30 72% C- 86% B
Price/Book Ratio 6.78 25% F 14% F
Price / Cash Flow Ratio -35.73 89% B+ 85% B
EV/EBITDA -20.72 88% B+ 90% A-
Management Effectiveness  
Return on Equity -29.57% 51% F 32% F
Return on Invested Capital -25.19% 45% F 30% F
Return on Assets -14.52% 45% F 27% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.63 78% C+ 70% C-
Short Percent 2.02% 67% D+ 59% F
Beta 1.38 38% F 30% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector